Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine in Chinese Patients with Indolent NHL
NCT01596621Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bendamustine in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Overall Response Rate up to 2.5 years. Started Aug 2012; status: completed.
02
Drugs
bendamustine
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT01596621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01596621.